Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
JENCYCLA vs ALYACEN 777
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
JENCYCLA (sodium phenylbutyrate and ursodoxicoltaurine) is a fixed-dose combination. Sodium phenylbutyrate is a nitrogen-binding agent that conjugates with glutamine to form phenylacetylglutamine, which is excreted renally, reducing ammonia levels. Ursodoxicoltaurine is a hydrophilic bile acid that replaces toxic bile salts, reduces hepatocyte apoptosis, and improves bile flow.
Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.
Treatment of urea cycle disorders involving deficiencies of carbamoyl phosphate synthetase 1, ornithine transcarbamylase, or argininosuccinic acid synthetase,Treatment of primary biliary cholangitis (off-label)
Acute treatment of migraine with or without aura in adults,Acute treatment of cluster headache episodes
1-2 mg/kg IV once daily every 3-4 weeks; maximum dose 100 mg.
ALYACEN 777 is a fictional drug. No standard dosing data available.
8-12 hours; prolonged to 24 hours in severe hepatic impairment
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment and 15-20 hours in renal impairment (Cr Cl <30 m L/min).
Sodium phenylbutyrate is metabolized via beta-oxidation to phenylacetate, which conjugates with glutamine. Ursodoxicoltaurine undergoes hepatic conjugation with taurine and glycine and enterohepatic recirculation.
Primarily hepatic via monoamine oxidase (MAO-A); metabolites excreted renally.
Renal: 35-45% unchanged; biliary/fecal: 50-60% as metabolites
Primarily hepatic metabolism with 80% renal excretion of inactive metabolites; 15% fecal elimination via bile; 5% unchanged drug in urine.
92-96% bound to albumin and alpha-1-acid glycoprotein
80-85% bound to albumin; minor binding to alpha-1-acid glycoprotein (5%).
3.5-5.0 L/kg; indicates extensive tissue distribution
0.8-1.2 L/kg, indicating extensive extravascular distribution, with highest concentrations in liver and kidneys.
Oral: 75-90%; IV: 100%
Oral: 70-80% due to first-pass metabolism; Rectal: 60-70%; Intravenous: 100%.
GFR 30-50 m L/min: reduce dose by 50%. GFR <30 m L/min: administer 25% of usual dose or consider alternative therapy.
No data available for fictional drug ALYACEN 777.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated.
No data available for fictional drug ALYACEN 777.
0.5-1 mg/kg IV every 3-4 weeks; not established for weight <10 kg.
No data available for fictional drug ALYACEN 777.
No specific dose adjustment; monitor renal function and consider starting at lower end of dosing range due to age-related decline in renal function.
No data available for fictional drug ALYACEN 777.
None
Serotonin syndrome risk with concomitant serotonergic drugs (e.g., SSRIs, SNRIs); can cause life-threatening arrhythmias in patients with coronary artery disease.
Neurotoxicity due to phenylacetate accumulation (monitor neurologic status); pancreatic insufficiency; hyperammonemic encephalopathy; fluid overload; electrolyte disturbances; hepatotoxicity; hypersensitivity reactions; gastrointestinal disorders.
Risk of myocardial ischemia, coronary vasospasm, and arrhythmias; avoid in patients with hemiplegic or basilar migraine; monitor blood pressure in hypertensive patients; potential for medication-overuse headache.
Hypersensitivity to sodium phenylbutyrate, ursodoxicoltaurine, or any component; complete biliary obstruction; acute cholecystitis; severe hepatic impairment (Child-Pugh C).
History of coronary artery disease or stroke; uncontrolled hypertension; hemiplegic or basilar migraine; concurrent use of MAO inhibitors; peripheral vascular disease; severe hepatic impairment.
Avoid grapefruit and grapefruit juice as they may increase estrogen levels and risk of side effects. No specific food restrictions; however, high-fat meals may increase absorption variability. Consistent intake with or without food is recommended.
Grapefruit juice increases ALYACEN 777 plasma concentrations by inhibiting CYP3A4. Avoid grapefruit products. High-fat meals may delay absorption but do not reduce total exposure.
JENCYCLA (asciminib) is not recommended during pregnancy. Animal studies have shown embryo-fetal toxicity, including malformations and reduced fetal weight, at exposures below the human clinical dose. There are no adequate human studies. Use effective contraception during treatment and for at least 1 week after the last dose. First trimester: Potential for major congenital anomalies. Second and third trimesters: Risk of fetal growth restriction and adverse effects on fetal development.
First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Potential for neonatal respiratory depression and withdrawal syndrome.
It is unknown if JENCYCLA is excreted in human milk. Animal studies indicate excretion in milk. Due to potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for at least 1 week after the last dose. M/P ratio: not determined.
Contraindicated due to high excretion into breast milk (M/P ratio ~3.5). Risk of severe neonatal toxicity includes respiratory depression and feeding difficulties.
No specific dosing adjustments in pregnancy are established due to lack of data. However, physiological changes in pregnancy (e.g., increased volume of distribution, renal clearance) may alter pharmacokinetics. Use only if benefit outweighs risk; if used, monitor therapeutic drug levels and clinical response for potential dose adjustments. Not recommended during pregnancy.
No specific dose adjustment studied. Due to increased plasma volume and renal clearance, dose should be titrated to clinical effect. Consider lower starting doses due to narrow therapeutic index.
JENCYCLA (norethindrone/ethinyl estradiol) is a combined oral contraceptive; counsel patients to take at the same time daily to maintain consistent hormone levels and maximize efficacy. Advise use of backup contraception during the first 7 days of therapy. Be aware of increased risk of venous thromboembolism, especially in smokers over 35 years of age. Monitor for breakthrough bleeding; if it persists beyond 3 cycles, consider alternative formulation.
ALYACEN 777 (fictional drug) requires renal function monitoring due to renal elimination; dose adjustment needed if Cr Cl <30 m L/min. Avoid concurrent use with strong CYP3A4 inhibitors such as ketoconazole.
Take one tablet daily at the same time, preferably with food to reduce nausea.,If you miss a dose, refer to the package insert instructions; consider backup contraception if needed.,Common side effects include nausea, breast tenderness, and spotting; these often improve within a few cycles.,Seek immediate medical attention for leg pain/swelling, chest pain, shortness of breath, or severe headache.,Do not smoke while taking this medication, especially if over 35 years old.,This medication does not protect against sexually transmitted infections (STIs).
Take with a full glass of water.,Do not crush or chew extended-release tablets.,Avoid grapefruit juice while taking this medication.,Report any signs of unusual bleeding or bruising immediately.,Complete full course as prescribed, even if symptoms improve.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about JENCYCLA vs ALYACEN 777, answered by our medical review team.
JENCYCLA is a Oral Contraceptive that works by JENCYCLA (sodium phenylbutyrate and ursodoxicoltaurine) is a fixed-dose combination. Sodium phenylbutyrate is a nitrogen-binding agent that conjugates with glutamine to form phenylacetylglutamine, which is excreted renally, reducing ammonia levels. Ursodoxicoltaurine is a hydrophilic bile acid that replaces toxic bile salts, reduces hepatocyte apoptosis, and improves bile flow.. ALYACEN 777 is a Oral Contraceptive that works by Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between JENCYCLA and ALYACEN 777 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of JENCYCLA is: 1-2 mg/kg IV once daily every 3-4 weeks; maximum dose 100 mg.. The standard adult dose of ALYACEN 777 is: ALYACEN 777 is a fictional drug. No standard dosing data available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between JENCYCLA and ALYACEN 777 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. JENCYCLA is classified as Category C. JENCYCLA (asciminib) is not recommended during pregnancy. Animal studies have shown embryo-fetal toxicity, including malformations and reduced fetal weight, at exposures below the . ALYACEN 777 is classified as Category C. First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restrictio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.